Northeast Investment Management lowered its position in CVS Health Corp (NYSE:CVS) by 1.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 287,431 shares of the pharmacy operator’s stock after selling 5,028 shares during the period. CVS Health comprises approximately 1.8% of Northeast Investment Management’s holdings, making the stock its 17th largest position. Northeast Investment Management’s holdings in CVS Health were worth $20,839,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of CVS. Wealthcare Advisory Partners LLC boosted its holdings in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 991 shares during the period. Fieldpoint Private Securities LLC boosted its holdings in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 1,000 shares during the period. Arcadia Investment Management Corp MI boosted its holdings in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after buying an additional 726 shares during the period. MPS Loria Financial Planners LLC bought a new position in CVS Health in the 2nd quarter worth $119,000. Finally, Cerebellum GP LLC bought a new position in CVS Health in the 4th quarter worth $130,000. 83.11% of the stock is owned by institutional investors.

Get CVS Health alerts:

Shares of CVS Health Corp (NYSE CVS) opened at $69.27 on Friday. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. The stock has a market cap of $69,353.41, a PE ratio of 10.71, a PEG ratio of 1.13 and a beta of 1.03. CVS Health Corp has a 1 year low of $66.45 and a 1 year high of $84.00.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.04. The firm had revenue of $48.39 billion for the quarter, compared to analysts’ expectations of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.71 EPS. sell-side analysts anticipate that CVS Health Corp will post 6.37 earnings per share for the current fiscal year.

In related news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by corporate insiders.

Several research analysts recently weighed in on the stock. Bank of America started coverage on shares of CVS Health in a report on Tuesday, February 27th. They issued a “buy” rating and a $91.00 target price for the company. Citigroup set a $77.00 price objective on shares of CVS Health and gave the company a “neutral” rating in a report on Tuesday, February 13th. Leerink Swann set a $85.00 price objective on shares of CVS Health and gave the company a “buy” rating in a report on Friday, February 9th. Robert W. Baird dropped their price objective on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Friday, February 9th. Finally, Royal Bank of Canada set a $89.00 price objective on shares of CVS Health and gave the company a “buy” rating in a report on Thursday, February 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $87.03.

TRADEMARK VIOLATION WARNING: “CVS Health Corp (CVS) Position Trimmed by Northeast Investment Management” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3252879/cvs-health-corp-cvs-position-trimmed-by-northeast-investment-management.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).